Genomic and phylogenetic analyses of SARS-CoV-2 strains isolated in the city of Gwangju, South Korea

Abstract Since the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China in late December 2019, the coronavirus disease 2019 (COVID-19) has spread fast around the world. RNA viruses, including SARS-CoV-2, have higher gene mutations than DNA viruses during viru...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Lee, Ji-Eun, Chung, Jae Keun, Tae Sun Kim, Park, Jungwook, Lim, Mi Hyeon, Da Jeong Hwang, Jeong, Jin, Kim, Kwang Gon, Ji-Eun Yoon, Hye Young Kee, Jin Jong Seo, Min Ji Kim
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 18.12.2020
Subjects
Coronaviridae
Coronaviruses
COVID-19
DNA biosynthesis
DNA viruses
Frameshift mutation
Genetic diversity
Genomes
Genomics
Mutation
Phylogenetics
Phylogeny
RNA viruses
Severe acute respiratory syndrome coronavirus 2
South Korea
Online AccessGet full text

Cover

More Information
Summary:Abstract Since the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China in late December 2019, the coronavirus disease 2019 (COVID-19) has spread fast around the world. RNA viruses, including SARS-CoV-2, have higher gene mutations than DNA viruses during virus replication. Variations in SARS-CoV-2 genome could contribute to efficiency of viral spread and severity of COVID-19. In this study, we analyzed the locations of genomic mutations to investigate the genetic diversity among isolates of SARS-CoV-2 in Gwangju. We detected non-synonymous and frameshift mutations in various parts of SARS-CoV-2 genome. The phylogenetic analysis for whole genome showed that SARS-CoV-2 genomes in Gwangju isolates are clustered within clade V and G. Our findings not only provide a glimpse into changes of prevalent virus clades in Gwangju, South Korea, but also support genomic surveillance of SARS-CoV-2 to aid in the development of efficient therapeutic antibodies and vaccines against COVID-19.
DOI:10.1101/2020.12.16.423178